WO2018203354A3 - Supramolecular compounds consisting of sodium hyaluronate, amino acids, linoleic acid, lycopene and resveratrol - Google Patents

Supramolecular compounds consisting of sodium hyaluronate, amino acids, linoleic acid, lycopene and resveratrol Download PDF

Info

Publication number
WO2018203354A3
WO2018203354A3 PCT/IT2018/000064 IT2018000064W WO2018203354A3 WO 2018203354 A3 WO2018203354 A3 WO 2018203354A3 IT 2018000064 W IT2018000064 W IT 2018000064W WO 2018203354 A3 WO2018203354 A3 WO 2018203354A3
Authority
WO
WIPO (PCT)
Prior art keywords
induction
regenerative
linoleic acid
supramolecular
resveratrol
Prior art date
Application number
PCT/IT2018/000064
Other languages
French (fr)
Other versions
WO2018203354A2 (en
Inventor
Gianmario MATTEI
Original Assignee
Mattei Gianmario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mattei Gianmario filed Critical Mattei Gianmario
Publication of WO2018203354A2 publication Critical patent/WO2018203354A2/en
Publication of WO2018203354A3 publication Critical patent/WO2018203354A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Abstract

The class of compounds presented belong to the chemical class called supramolecular. Their preparation can be obtained through the sequential reaction of molecules such as sodium hyaluronate, essential or non-essential amino acids, linoleic acid, lycopene and resveratrol in a reaction system containing bidistilled water. The supramolecular compounds presented have high capacities for biological and antioxidant induction, such as to be equally effective in anti-aging treatments, in the regenerative induction of damaged epidermal layers, in the regenerative induction of corneous and connective tissues, in the regenerative induction of cartilaginous tissues, in the regenerative induction of synovial fluids, in the regenerative and restorative induction of muscle fibers. The supramolecular compounds can also perform anti-inflammatory and pain-relieving functions thanks to the presence of linoleic acid, a substance that naturally modulates the inflammatory response to anti- pain in humans.
PCT/IT2018/000064 2017-05-05 2018-05-07 Supramolecular compounds constituted by hyaluronic acid, sodium, essential amino acids and non essential, linoleic acid, lycopene and resveratrol WO2018203354A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000048653A IT201700048653A1 (en) 2017-05-05 2017-05-05 SUPRAMOLECULAR COMPOUNDS CONSISTING OF HYALURONIC ACID, SODIUM, ESSENTIAL (OR NON-ESSENTIAL) AMINO ACIDS, LINOLEIC ACID, LYCOPENE AND REVESTRADIOL.
IT102017000048653 2017-05-05

Publications (2)

Publication Number Publication Date
WO2018203354A2 WO2018203354A2 (en) 2018-11-08
WO2018203354A3 true WO2018203354A3 (en) 2018-12-13

Family

ID=61005883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2018/000064 WO2018203354A2 (en) 2017-05-05 2018-05-07 Supramolecular compounds constituted by hyaluronic acid, sodium, essential amino acids and non essential, linoleic acid, lycopene and resveratrol

Country Status (2)

Country Link
IT (1) IT201700048653A1 (en)
WO (1) WO2018203354A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008061A1 (en) * 1998-08-05 2000-02-17 Jasper Ltd. Liability Co. Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
DE19923829A1 (en) * 1999-05-17 2000-11-23 Ulrich Kluegel Complex of hyaluronate, active ingredient and water, useful as topical pharmaceutical or cosmetic composition, is stable and has high content of active agent
EP1591105A1 (en) * 2004-03-17 2005-11-02 Stada Arzneimittel Ag Use of antioxidants for the preparation of pharmaceutical or cosmetic compositions for protecting the skin from damages by infrared-radiations
DE102004062597A1 (en) * 2004-09-10 2006-03-30 Martin Holzlehner Method to modify hyaluronate gel to produce a supramolecular gel, useful e.g. as medicine product to treat skin problems, comprises agitating aqueous hyaluronate solution for long time, exposing to UV radiation and distilling the solution
WO2007136586A2 (en) * 2006-05-17 2007-11-29 E. I. Du Pont De Nemours And Company Personal care compositions
US20150224069A1 (en) * 2011-08-01 2015-08-13 Tixupharma Method of treatment of periodontum and damaged oral tissue by administering oral compositions comprising supramolecular complexes of polyanionic polymers and spermidine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008061A1 (en) * 1998-08-05 2000-02-17 Jasper Ltd. Liability Co. Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
DE19923829A1 (en) * 1999-05-17 2000-11-23 Ulrich Kluegel Complex of hyaluronate, active ingredient and water, useful as topical pharmaceutical or cosmetic composition, is stable and has high content of active agent
EP1591105A1 (en) * 2004-03-17 2005-11-02 Stada Arzneimittel Ag Use of antioxidants for the preparation of pharmaceutical or cosmetic compositions for protecting the skin from damages by infrared-radiations
DE102004062597A1 (en) * 2004-09-10 2006-03-30 Martin Holzlehner Method to modify hyaluronate gel to produce a supramolecular gel, useful e.g. as medicine product to treat skin problems, comprises agitating aqueous hyaluronate solution for long time, exposing to UV radiation and distilling the solution
WO2007136586A2 (en) * 2006-05-17 2007-11-29 E. I. Du Pont De Nemours And Company Personal care compositions
US20150224069A1 (en) * 2011-08-01 2015-08-13 Tixupharma Method of treatment of periodontum and damaged oral tissue by administering oral compositions comprising supramolecular complexes of polyanionic polymers and spermidine

Also Published As

Publication number Publication date
WO2018203354A2 (en) 2018-11-08
IT201700048653A1 (en) 2018-11-05

Similar Documents

Publication Publication Date Title
AR114031A2 (en) BINDING MOLECULES A 4-1BB
EA201590540A1 (en) C17-ALKANDILE AND ALKANDILE DERIVATIVES OF OLEANOLIC ACIDS AND METHODS FOR THEIR APPLICATION
BR112016030424A2 (en) multispecific antibody constructs
CR20110639A (en) MUTANTS FGF21 AND USES OF THE SAME
EA201591426A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
CL2010001475A1 (en) Compounds derived from boronate ester, proteasome inhibitors; pharmaceutical compositions containing them; procedure for preparing the pharmaceutical composition; Useful in the treatment of cell proliferative diseases, particularly cancer.
EA201391313A1 (en) C4-MONOMETILTRITERPENOID DERIVATIVES AND METHODS OF THEIR APPLICATION
MX363015B (en) Roseburia flagellin and immune modulation.
BR112016001974A2 (en) process for the preparation of a particle, particle obtained from the process, liquid composition, household care or personal care composition and method of treating a substrate
EA201590881A1 (en) THERAPEUTIC CONNECTIONS AND COMPOSITIONS AND THEIR USE AS MODULATORS PK-M2
EA201390894A1 (en) Pyrazole and pyrimidinyl tricyclic enons as anti-oxidant modulators of inflammation
CY1123056T1 (en) NEW FORM OF ADMINISTRATION OF RACECADOTRIL
MX2021008318A (en) Novel specific-binding polypeptides and uses thereof.
BR112012016114B8 (en) method for forming an inhibitor-treated amine
BR112012029837A2 (en) polymer-bound perylene dyes and compositions containing them
BR112014028991A2 (en) triazoles as kv3 inhibitors
BR112013003722A2 (en) care products and methods of use and manufacture
CL2008002537A1 (en) Compounds derived from 6-phenyl-nicotinic acid, with ppar-alpha modulating activity; preparation procedure; pharmaceutical composition comprising them; and its use to treat and / or prevent dyslipidemias, arteriosclerosis and heart failure.
BR112015022747A2 (en) gastrointestinal obstruction prevention materials
BR112014011254A2 (en) 2-thiopyrimidinones
WO2014076321A8 (en) Novel specific-binding polypeptides and uses thereof
CL2015002692A1 (en) Novel benzenesulfonamide compounds, method to synthesize them and use of the compounds in medicine and cosmetics.
EA201170116A1 (en) PHOSPHATE-BINDING MATERIALS AND THEIR APPLICATION
BR112014024220A2 (en) genes that encode cellulase
BR112013019394A2 (en) use of an agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18737728

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18737728

Country of ref document: EP

Kind code of ref document: A2